Search Results - "GODFREY, Wayne R"

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer by KANTOFF, Philip W, SCHUETZ, Thomas J, DAHUT, William L, ARLEN, Philip M, GULLEY, James L, GODFREY, Wayne R, BLUMENSTEIN, Brent A, GLODE, L. Michael, BILHARTZ, David L, WYAND, Michael, MANSON, Kelledy, PANICALI, Dennis L, LAUS, Reiner, SCHLOM, Jeffrey

“…Therapeutic prostate-specific antigen (PSA) -targeted poxviral vaccines for prostate cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for…”
Get full text

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma by Gopal, Ajay K, Kahl, Brad S, de Vos, Sven, Wagner-Johnston, Nina D, Schuster, Stephen J, Jurczak, Wojciech J, Flinn, Ian W, Flowers, Christopher R, Martin, Peter, Viardot, Andreas, Blum, Kristie A, Goy, Andre H, Davies, Andrew J, Zinzani, Pier Luigi, Dreyling, Martin, Johnson, Dave, Miller, Langdon L, Holes, Leanne, Li, Daniel, Dansey, Roger D, Godfrey, Wayne R, Salles, Gilles A

“…Idelalisib, which inhibits PI3K isoform delta, produced antitumor responses in nearly 60% of pretreated patients with indolent non-Hodgkin's lymphomas…”
Get full text

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) by Kahl, Brad S., Spurgeon, Stephen E., Furman, Richard R., Flinn, Ian W., Coutre, Steven E., Brown, Jennifer R., Benson, Don M., Byrd, John C., Peterman, Sissy, Cho, Yoonjin, Yu, Albert, Godfrey, Wayne R., Wagner-Johnston, Nina D.

“…Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase δ (PI3Kδ), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling…”
Get full text

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma by Flinn, Ian W., Kahl, Brad S., Leonard, John P., Furman, Richard R., Brown, Jennifer R., Byrd, John C., Wagner-Johnston, Nina D., Coutre, Steve E., Benson, Don M., Peterman, Sissy, Cho, Yoonjin, Webb, Heather K., Johnson, David M., Yu, Albert S., Ulrich, Roger G., Godfrey, Wayne R., Miller, Langdon L., Spurgeon, Stephen E.

“…Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-δ, was evaluated in a phase I study in 64 patients with relapsed indolent…”
Get full text

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma by de Vos, Sven, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian W., Schreeder, Marshall T., Fowler, Nathan H., Sharman, Jeff P., Boccia, Ralph V., Barrientos, Jacqueline C., Rai, Kanti R., Boyd, Thomas E., Furman, Richard R., Kim, Yeonhee, Godfrey, Wayne R., Leonard, John P.

“…Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent…”
Get full text

NF90 regulates inducible IL-2 gene expression in T cells by Shi, Lingfang, Godfrey, Wayne R, Lin, Joseph, Zhao, Guohua, Kao, Peter N

“…Activation of T cells induces the production of T cell growth and survival factor interleukin (IL) 2. Regulatory T cells intrinsically fail to induce IL-2…”
Get full text

In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures by Godfrey, Wayne R., Ge, Ying G., Spoden, Darrin J., Levine, Bruce L., June, Carl H., Blazar, Bruce R., Porter, Stephen B.

“…CD4+CD25+ T-regulatory (Treg) cells have been shown to critically regulate self- and allograft tolerance in several model systems. Studies of human Treg cells…”
Get full text

Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function by Godfrey, Wayne R., Spoden, Darrin J., Ge, Ying G., Baker, Seth R., Liu, Baoling, Levine, Bruce L., June, Carl H., Blazar, Bruce R., Porter, Stephen B.

“…CD4+CD25+ T regulatory (Treg) cells have been shown to critically regulate self and allograft tolerance in mice. Studies of human Treg cells have been hindered…”
Get full text

CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy by Li, Lequn, Godfrey, Wayne R., Porter, Stephen B., Ge, Ying, June, Carle H., Blazar, Bruce R., Boussiotis, Vassiliki A.

“…CD4+CD25+ regulatory T cells (Tregs) are essential negative regulators of immune responses. Here, we examined the signaling properties of human Tregs, using…”
Get full text

Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation by Godfrey, Wayne R., Krampf, Mark R., Taylor, Patricia A., Blazar, Bruce R.

“…Eliminating alloreactive cells from T-cell populations would enable the transfer of immune function to patients who receive stem cell transplants. However,…”
Get full text

Robust B Cell Immunity but Impaired T Cell Proliferation in the Absence of CD134 (OX40) by Pippig, Susanne D, Pena-Rossi, Claudia, Long, James, Godfrey, Wayne R, Fowell, Deborah J, Reiner, Steven L, Birkeland, Marian L, Locksley, Richard M, Barclay, A. Neil, Killeen, Nigel

“…CD134 (OX40) is a member of the TNF receptor family that is expressed on activated T lymphocytes. T cells from mice that lack expression of CD134 made strong…”
Get full text

NF90 Regulates Cell Cycle Exit and Terminal Myogenic Differentiation by Direct Binding to the 3′-Untranslated Region of MyoD and p21WAF1/CIP1 mRNAs by Shi, Lingfang, Zhao, Guohua, Qiu, Daoming, Godfrey, Wayne R., Vogel, Hannes, Rando, Thomas A., Hu, Hong, Kao, Peter N.

“…NF90 and splice variant NF110/ILF3/NFAR are double-stranded RNA-binding proteins that regulate gene expression. Mice with targeted disruption of NF90 were…”
Get full text

Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323) by Keyt, Bruce, Baliga, Ramesh, Li, Keyu, Manlusoc, Marigold, Hinton, Paul, Ng, Dean, Tran, Madeline, Shan, Bing, Lu, Hai, Rahman, Sachi, Saini, Avneesh, Cao, Yuan, Saraiya, Chitra, Peterson, Marvin, Godfrey, Wayne R, Carroll, Steve

“…Abstract only e15007 Background: Bispecific antibodies which tether T-cells to cancer cells, and additionally activate T-cell mediated killing, have shown…”
Get full text

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results by de Vos, Sven, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian, Schreeder, Marshall T., Fowler, Nathan, Sharman, Jeff P., Boccia, Ralph V., Barrientos, Jaqueline C., Rai, Kanti R., Boyd, Thomas E, Furman, Richard R., Holes, Leanne M., Kim, Yeonhee, Godfrey, Wayne R., Leonard, John P.

“…Introduction: PI3K-delta signaling is critical for activation, proliferation and survival of B cells, and is hyperactive in many B-cell malignancies…”
Get full text

Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) by Gopal, Ajay K., Kahl, Brad S., de Vos, Sven, Wagner-Johnston, Nina D., Schuster, Stephen J., Jurczak, Wojciech, Flinn, Ian W., Flowers, Christopher R., Martin, Peter, Viardot, Andreas, Blum, Kristie A., Goy, Andre, Davies, Andrew, Zinzani, Pier Luigi, Dreyling, Martin H., Holes, Leanne M., Sorensen, Bess, Godfrey, Wayne R., Salles, Gilles Andre

“…Introduction: Rituximab-alkylator combinations are the standard therapies for patients (pts) with iNHL, however, refractory disease nearly uniformly develops…”
Get full text

Reply to L. León et al by Kantoff, Philip W., Blumenstein, Brent A., Gulley, James L., Godfrey, Wayne R.

Get full text

A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL) by De Vos, Sven, Sehn, Laurie Helen, Mulligan, Stephen P., Dreyling, Martin H., Rummel, Mathias J., Zinzani, Pier Luigi, Johnson, David Michael, Evans, Shelley, Dansey, Roger D., Godfrey, Wayne R., Czuczman, Myron Stefan

“…Abstract only TPS8618 Background: PI3K-delta is critical for activation, proliferation and survival of B cells and plays a role in homing and retention in…”
Get full text

Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer by McLeod, David G., Adams, George W., Gittleman, Marc C., Bihartz, David L., Reiling, Richard B., Ruiz, Henry E., Cochran, James S., Prettyman, Julie, Delcayre, Alain, Godfrey, Wayne R., Legrand, Fatema A., Mann, Grace, Bandman, Olga

“…Abstract only 193 Background: MVA-BN-PRO is an investigational prostate cancer immunotherapy comprising of a highly attenuated non-replicating vaccinia virus…”
Get full text

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) by Gopal, Ajay, Kahl, Brad S., De Vos, Sven, Wagner-Johnston, Nina D., Schuster, Stephen J., Blum, Kristie A., Jurczak, Wojciech J., Flinn, Ian W., Flowers, Christopher R., Martin, Peter, Viardot, Andreas, Goy, Andre, Davies, Andrew, Zinzani, Pier Luigi, Dreyling, Martin H., Holes, Leanne M., Li, Daniel, Dansey, Roger, Godfrey, Wayne R., Salles, Gilles A.

“…Alkylating agent-rituximab combinations are a current standard of care for patients with iNHL. Most iNHL will eventually become refractory to current…”
Get full text

Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study by Leonard, John, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian, Schreeder, Marshall T., Fowler, Nathan Hale, Sharman, Jeff Porter, Boccia, Ralph V., Barrientos, Jacqueline Claudia, Rai, Kanti Roop, Boyd, Thomas E., Furman, Richard R., Holes, Leanne, Johnson, David Michael, Kim, Yeonhee, Dansey, Roger D., Godfrey, Wayne R., De Vos, Sven

“…Abstract only 8500 Background: PI3K-delta signaling is critical for activation, proliferation and survival of B cells, and is hyperactive in many B-cell…”
Get full text